Bicycle Therapeutics under investigation for potential securities fraud.

jueves, 11 de diciembre de 2025, 10:21 am ET1 min de lectura
BCYC--

• Pomerantz LLP investigates Bicycle Therapeutics plc securities fraud claims. • Investors advised to contact Danielle Peyton at [email protected] or 646-581-9980. • RBC Capital Markets analyst Leonid Timashev downgraded Bicycle to Sector Perform. • Delays in zelenectide pevedotin development cited. • Competing Pfizer product sales may benefit from further Bicycle delays. • Urothelial cancer treatment space becomes increasingly competitive.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios